Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 1—January 2005

Research

Human Parechovirus-3 and Neonatal Infections

Guy Boivin*Comments to Author , Yacine Abed*, and François D. Boucher*
Author affiliations: *Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Québec, Canada

Main Article

Appendix

Figure. Comparison of the predicted amino acid sequences of human parechovirus (HPeV)-3 Canadian isolates no. 81235, 81554, and 82853 with reference sequences of HPeV-1, -2 and -3 (GenBank accession no. S45208, AF055846, and AB084913, respectively) for the VP0-VP3-VP1 proteins (8,10). Asterisks denote identical residues in all strains, whereas shaded amino acids highlight changes between HPeV-3 isolates. The RGD motif present only in HPeV-1 and -2 strains is underlined. The HPeV-1 immunodominant

Appendix. Figure. Comparison of the predicted amino acid sequences of human parechovirus (HPeV)-3 Canadian isolates no. 81235, 81554, and 82853 with reference sequences of HPeV-1, -2 and -3 (GenBank accession no. S45208, AF055846, and AB084913, respectively) for the VP0-VP3-VP1 proteins (8,10). Asterisks denote identical residues in all strains, whereas shaded amino acids highlight changes between HPeV-3 isolates. The RGD motif present only in HPeV-1 and -2 strains is underlined. The HPeV-1 immunodominant epitope described by Joki-Korpela et al. (15) is shown in bold.

Main Article

TOP